Is Combining Chemo and an Oral EGFR Inhibitor Helpful, Harmful, or Neither?

Article

A central question since the introduction of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) like Tarceva (erlotinib) and Iressa (gefitinib) has been how best to use them. Specifically, one standard way that we integrate new agents in cancer care is to combine them with the treatment that is our current standard of care.